2022
Primary Care Associated With Follow Up Viral Load Testing in Patients Cured of Hepatitis C Infection With Direct Acting Antivirals at a Multidisciplinary Addiction Treatment Program: Insights From a Real-World Setting
Haque LY, Butner JL, Shi JM, Henry S, Deng Y, Ciarleglio MM, Madden LM, Tetrault JM. Primary Care Associated With Follow Up Viral Load Testing in Patients Cured of Hepatitis C Infection With Direct Acting Antivirals at a Multidisciplinary Addiction Treatment Program: Insights From a Real-World Setting. Journal Of Addiction Medicine 2022, 16: 333-339. PMID: 34483278, PMCID: PMC9033626, DOI: 10.1097/adm.0000000000000910.Peer-Reviewed Original ResearchConceptsHepatitis C virus infectionUrine toxicology resultsDirect acting antiviralsViral load testingSubstance use disordersAddiction treatment programsHCV reinfectionActing antiviralsToxicology resultsUse disordersDirect acting antiviral therapyTreatment programReal-world clinical settingHCV reinfection ratesActing antiviral (DAA) therapyC virus infectionHepatitis C infectionMedical service useCohort of patientsPrimary medical careSubstance use statusAddiction treatment settingsQuality improvement initiativesHCV cureC infectionDevelopment and pilot-testing of a hepatitis C reinfection prevention intervention for patients in treatment for hepatitis C infection
Viera A, Grau L, Fisher J, Farnum S, Tetrault J, Scott G, Heimer R. Development and pilot-testing of a hepatitis C reinfection prevention intervention for patients in treatment for hepatitis C infection. Drug And Alcohol Dependence Reports 2022, 3: 100038. PMID: 36845980, PMCID: PMC9948939, DOI: 10.1016/j.dadr.2022.100038.Peer-Reviewed Original Research
2020
Substance Use Disorders in Recently Hospitalized Patients With Cirrhosis.
Haque LY, Jakab S, Deng Y, Ciarleglio MM, Tetrault JM. Substance Use Disorders in Recently Hospitalized Patients With Cirrhosis. Journal Of Addiction Medicine 2020, 14: e337-e343. PMID: 32530887, PMCID: PMC9033633, DOI: 10.1097/adm.0000000000000677.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersAddiction treatmentAlcohol-related liver diseaseImpact of SUDHepatitis C infectionMedical record reviewMinority of patientsNumber of hospitalizationsRoutine clinical careAlcohol use disorderHepatology clinicC infectionCause mortalityConsecutive patientsMedian ageCommon etiologyLiver diseaseRecord reviewSignificant morbidityRetrospective studySUD careCirrhosisClinical careHospitalization
2016
Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection
Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Re V, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas MC, Fiellin LE, Bryant K, Justice AC, Fiellin DA. Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. Journal Of Substance Use And Addiction Treatment 2016, 68: 62-67. PMID: 27431048, PMCID: PMC4976086, DOI: 10.1016/j.jsat.2016.06.002.Peer-Reviewed Original ResearchConceptsLiver enzyme elevationAlcohol use disorderUninfected patientsHepatotoxic medicationsHCV infectionUse disordersComposite endpointLiver injuryHIV/HCV co-infected patientsHCV co-infected patientsHIV/HCV statusPre-existing liver injuryCo-infected patientsCohort of HIVHepatitis C infectionHIV/HCVOpioid use disorderRisk of hepatotoxicityHCV statusHepatic safetyMedian ALTC infectionChart reviewEnzyme elevationHIV infection